Novo Nordisk says CagriSema beats tirzepatide for weight loss in Phase 3
The head-to-head comparison pits Novo's cagrilintide-semaglutide combination against Eli Lilly's marketed dual agonist in a late-stage trial.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 22 10:50 ETSource: BioPharm International
The wire
- 01Novo Nordisk reported that CagriSema produced greater weight loss than tirzepatide in a Phase 3 head-to-head trial.
- 02A win over tirzepatide would reshape prescribing and payer positioning in the incretin market, where Zepbound currently leads on weight-loss data.
- 03Full trial data, tolerability details and regulatory timing have not been detailed here; the results come from the sponsor.
From the source
Read at biopharminternational.comNovo Nordisk's CagriSema Beats Tirzepatide for Weight Loss in Phase 3 Trial
